Teamwork Financial Advisors LLC Sells 1,994 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Teamwork Financial Advisors LLC lowered its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 73.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 723 shares of the pharmaceutical company's stock after selling 1,994 shares during the period. Teamwork Financial Advisors LLC's holdings in Vertex Pharmaceuticals were worth $351,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Capital World Investors boosted its stake in shares of Vertex Pharmaceuticals by 5.7% in the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company's stock valued at $11,406,667,000 after purchasing an additional 1,514,993 shares during the period. Vanguard Group Inc. lifted its holdings in Vertex Pharmaceuticals by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 23,258,288 shares of the pharmaceutical company's stock worth $9,366,113,000 after buying an additional 98,654 shares in the last quarter. Capital Research Global Investors boosted its position in Vertex Pharmaceuticals by 15.8% in the 4th quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company's stock valued at $4,199,713,000 after buying an additional 1,426,746 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Vertex Pharmaceuticals by 23.3% during the fourth quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company's stock valued at $2,382,407,000 after acquiring an additional 1,117,214 shares in the last quarter. Finally, Loomis Sayles & Co. L P increased its position in shares of Vertex Pharmaceuticals by 23.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 3,772,789 shares of the pharmaceutical company's stock worth $1,519,302,000 after acquiring an additional 704,575 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on VRTX shares. Morgan Stanley raised their price objective on Vertex Pharmaceuticals from $462.00 to $464.00 and gave the company an "equal weight" rating in a research note on Tuesday, May 6th. Leerink Partners reissued a "market perform" rating and set a $503.00 price target (down from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and lifted their price objective for the stock from $408.00 to $424.00 in a report on Tuesday, February 11th. Erste Group Bank cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $515.04.

Vertex Pharmaceuticals Stock Down 0.5%

Shares of VRTX traded down $2.03 during trading hours on Thursday, reaching $443.82. The company's stock had a trading volume of 1,399,850 shares, compared to its average volume of 1,417,462. The company has a 50 day moving average of $466.51 and a two-hundred day moving average of $460.41. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The firm has a market cap of $113.97 billion, a price-to-earnings ratio of -201.74, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. During the same period last year, the company posted $4.76 earnings per share. The company's revenue was up 2.6% compared to the same quarter last year. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the transaction, the executive vice president now owns 26,512 shares in the company, valued at $13,256,000. This trade represents a 10.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.